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 Hypertrophic Cardiomyopathy (HCM) is a disease which presents a distinct 
morphological change in cardiac tissue.  Pathology of the disease widely ranges from 
being largely asymptomatic to the sudden onset of cardiac death.  The disease’s etiology 
stems from genetic mutations in various components of the sarcomere such as the myosin 
binding regions.  One particular mutation affecting calcium handling in the sarcoplasmic 
reticulum, JPH-2, manifests as a possible mechanism for the onset of sudden death and 
histological features consistent with myocardial disarray.  This thesis aims to understand 
junctional complex gene’s, JPH-2, maintenance of the dyadic cleft and how mutants 
variants result in pathogenesis of HCM.    
 Hypertrophic Cardiomyopathy’s clinical presentation is highlighted in the 
subsequent case study, of Paco Sanchez.  The case study seeks to emphasis the use of 
laboratory diagnostics and treatment of HCM. The social effects of HCM and treatment 
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Chapter I: Overview of Hypertrophic Cardiomyopathy 
Introduction 
Hypertrophic cardiomyopathy is a disease characterized by the enlargement of the 
myocardium, the thick middlemost layer of cardiac tissue.  This enlargement is the cause 
of a wide range of abnormal pathologies of the heart, manifesting into a large variety of 
symptoms including irregular heart rhythms, valvular abnormalities (particularly in the 
mitral valve), shortness of breath, or chest pains.  However, Hypertrophic 
Cardiomyopathy (HCM) is notorious for being one of the leading causes of sudden 
cardiac death, especially in the demographic of physically active individuals; sudden 
cardiac death is often ascribed many similar physiological factors to HCM, such as 
asynchronous heart beats and enlargement of cardiac tissue.  
 Although the scope of the disease is statistically minute (affecting 0.05% of the 
patient population), a strong correlation within the epidemiology of HCM can be seen.  A 
strong genetic basis is observed within 25% of nuclear relatives signifying dominant 
phenotypic expression within family pedigrees (Bope, 2013).   Several genetic defects 
within a family of cardiac microfilament genes   are responsible for the causation of 
HCM; however penetrance is variable leading to asymptomatic individuals and those 
with more extreme physiological conditions.  The focus of many studies goes into the 
mutations of sacromeric component genes involving myosin heavy-chains and troponin 
such as the MYHY and MYBPC3 genes.   
Treatment of HCM is limited to invasive procedures involving surgery to ablate 
overgrowth of tissue or to maintain the electrochemical integrity.  More so, clinical 
presentation is hard to detect as the variable nature of HCM symptoms can lead to 
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diagnoses of other cardiac or metabolic diseases.  Thus, the use of familial screening and 
echocardiogram testing is pertinent due to the nature of HCM.   
Clinical Presentation: 
 HCM manifests itself in a variety of cardiac conditions stemming from the 
abnormal increase of myocardial tissue in the heart.  Most commonly, the left ventricle 
shows hypertrophy of the myocardium (the left ventricle is notably the area of the heart 
in which the myocardium of a physiologically normal heart is the thickest) or the septum 
which divides the left and right ventricles.  This enlargement in the left ventricle or 
septum ranges from 50 - 60mm in thickness, generally focused within the apex of the 
heart.  The increase in myocardial tissue in some individuals has effects upon the systolic 
and diastolic functions of the heart.  Due to misalignment of contractile subunits of the 
cardiac tissue, outflow from the left ventricle to the left atrium is more difficult for 
patients with HCM (Shah, 2012).  Increase in pressures of greater than 30mmHg within 
the ventricle, creates stress upon contraction and mitral valve regurgitation.  Since the 
pressure within the left ventricle is larger, the contraction creates stress which forces the 
heart to increase oxygen demand (Bonow, 2012).   
Ventricular hypertrophy’s effect in the mitral valves is also documented in the 
observation of abnormal valvular motion.  During systole, the high pressure gradient 
within the left ventricle causes blood outflow at a much higher velocity causing a 
hydrodynamic event known as the Venturi effect.  As explained by the Venturi effect, 
fluid flowing into a constricted system from a system with a larger cross sectional area 
experiences a decrease in pressure; this change in pressure when blood is flowing from a 
contracted ventricle to the atria is hypothesized to cause the mitral leaflets to move 
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towards the septum at an approximate 90
o 
from the hydrodynamic forces (Bonow, 2012).  
This is often observed using Doppler imaging, (as in Figure 1.) and is labeled Systolic 
anterior motion; such imaging often can explain other abnormalities such as mitral 
regurgitation.    Another theory contributing to abnormal valvular movement is abnormal 
positioning of the papillary muscles which connect the valves to the walls of the ventricle 
(Bope, 2013).  Over 25% of patients with HCM have ventricular or septal obstructions 
causing problems associated with the pressure gradient within the ventricles (Cirino, 
2011).  Ventricular obstructions caused by an abnormal gradient are an important facet in 
the clinical presentation of HCM; however its manifestation is not necessarily indicative 
of increased risk of sudden cardiac death (sans risk of progressive heart failure).   
 
Figure 1.  Doppler imaging of patient with Hypertrophic Cardiomyopathy.  In image 
A, SAM can be indicated by the abnormal mitral valve moving towards the septum 
(labeled S above LV).  Septal wall thickness can also be seen in Image B.  Colored 
Doppler imagery may reveal systolic gradients used to help diagnose HCM (Shah, 2012).   
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Patients with HCM often manifest symptoms associated with atrial fibrillation 
such as angina, syncope, or postural hypotension.  Indication of atrial fibrillation is 
generally detected in an electrocardiogram by the presence of the P waves in the PQRS 
complex.  Complaints of chest pain as well as shortness of breath are correlated to the 
diastolic function of the obstructed ventricle developing large intercavity pressure.  
Irregular beating of the heart can cause those with HCM, to have bouts of 
unconsciousness due to hypotension.  
Atrial fibrillation, withstanding other complications of HCM, is capable of 
inducing a multitude of fatal conditions, such as heart failure or formation of 
thromboembolisms due to impaired blood flow.  Ventricular arrhythmias have been 
correlated to increased incidence of sudden cardiac death by about 10 - 20% due to the 
frequency of atrial/ventricular fibrillation in symptomatic individuals (Elliot et al, 2000).  
The mechanism for the onset of sudden cardiac death via HCM is currently unknown; 
however studies have indicated that myocardial disarray is a major culprit in the onset of 
cardiac death.   
Genetics/Pathophysiology 
 Although the overall pathophysiology of HCM is not well understood, the 
genomics of the disease has been catalogued to mutations within 14 sacromeric genes.  
These genes include sequences which encode for myosin heavy chains, actin, and etc.  
Over 900 different mutations within the 14 sequences have been known to cause 
hypertrophic cardiomyopathy.  HCM mutations are often carried down in a dominant 
phenotypic fashion with variable expressivity.  Individuals can often exhibit variable 
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penetrance as a number of those with HCM are often asymptomatic; in contrast some 
develop serious cardiac complications associated with arrhythmia.   
 The variance of symptoms often leads to questions on the mechanisms of how 
HCM can clinically manifest itself in some patients but not others.  This is especially true 
in cases of sudden cardiac death; many patients often do not realize they have genetic 
mutations causing Hypertrophic Cardiomyopathy until fatal incidence of heart failure.  
The difficulty of diagnosing HCM in patients with cardiac problems adds to the difficulty 
in linking asymptomatic versus symptomatic presentations to specific gender or ethnic 
populations.  Although the phenotypic expression of HCM has no definite correlation 
within populations, the genotypic presence of the mutations causing HCM is transmitted 
in an autosomal dominant fashion.   
This facet of many sacromeric mutations causing HCM can provide clinical 
insight in establishing a management plan.  Based on information provided by 
GeneReviews on Familial Hypertrophic Cardiomyopathy, analyzing the pedigree of an 
individual of symptomatic HCM shows a 90% correlation their progeny developing 
variable symptomology (Cirino, 2011).  Variance of symptoms can also be a result of a 
wide variety of different mutations which may independently cause HCM; these 
mutations affect different parts of the sacromere and may have slightly different 
pathologies associated with some.      
The most common mutations in symptomatic HCM are caused by missense 
mutations within the myosin heavy chains coding for the head and neck regions or the 
myosin binding proteins.  Of the many HCM- causing mutations, MYH7 and MYBPC3 
are responsible for 80% of HCM cases (Cirino, 2011).  MYH7 encodes for the myosin 
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heavy ß-chain, and has the function of maintaining the slow twitch of cardiac muscle 
fibers (Quiat et al, 2011).  Expression of this protein product is normally localized in the 
ventricle of humans as well as the atria of some failing hearts.  Mutations occurring 
within the gene MYH7 afflict the amino head and hinge of the coded protein (OMIM: 
160760).  Analysis of MYH7 mutations has shown that missense mutations code for 
amino acid substitutions, specifically the Arginine to Glutamine mutation on amino acid 
location 403, evident in Figure 2.  Such mutations are hypothesized to cause lower sliding 
velocity during myosin and actin interaction and therefore lead to overall all abnormal 
contractions (Kelly & Strauss, 1994).  In contrast some mutations such as the D778G 
MYH7 mutants, have been observed to increase actin sliding by approximately 30-50%; 
the theoretical mechanism of how such mutants cause abnormal cardiac function is 
consequence of faster actin myosin cross bridging which breaks down ATP (ADP + PI) 
faster than the myocyte can produce (Reverra et al., 2007).  This build up of ADP and 





Figure 2.  Mutations known to cause Hypertrophic Cardiomyopathy. These 
mutations correlate with the Head and Rod region of ß Myosin Heavy Chain.  Many 
MYH7 mutations corresponding to different parts of the Myoin heavy chain dimer, can 
cause clinical manifestations of abnormal cardiac function.  Arg403Gln, is one specific 
mutation known to have higher incidence of sudden cardiac death associated with 
ventricular arrhythmia.  Many other missense mutations occur along the head region of 
myosin heavy chain or the head/rod intersect.  (Kelly & Strauss, 1994) 
 
 MYBPC3 encodes for cardiac binding proteins, more specifically Cardiac 
Binding Protein C; such proteins play roles in the contraction by the ATP dependent 
process of myosin binding or response to sympathetic activity (OMIM: 600958).  Various 
mutations, such as missense, deletions and insertions in the sequence (located on 
11p11.2), cause truncations in the protein product leading to Hypertrophic 
Cardiomyopathy.  Mutations in this gene also cause sacromeric disorganization as well as 
decreased force generation.   As seen in Figure 3, proper binding of the myosin head as 
well as proper sliding of actin/myosin is ideal in cardiac function; mutations in either the 
ß myosin heavy chain or the cardiac binding protein, (MYH7 and MYBPC3, 




Figure 3.  Contraction by interactions of thin and thick filaments as a result of 
calcium mediated binding events.  ATPase activity triggers the binding of actin to the 
head; the binding of the myosin head to actin causes sliding events which leads to 
contraction.  Mutations in the myosin protein complex have been shown to increase or 
decrease sliding velocities causing abnormal pathology. (Cirino, 2011) 
Although mutations in the myosin-actin complex have a large contribution in the 
overall symptomology of HCM, mutations in the calcium channels of the sacromere are 
found to contribute to the large incidence of sudden cardiac death.  JPH2, proteins which 
mediate calcium release in the sacromere, have been found to contribute to this increased 
incidence.  By impairing synchronny events of calcium influx into the cells, mutations in 
JPH2 can cause ventricular arrythimias which have the probability of leading to sudden 
cardiac death (Landstrom, 2007).  The mechanism of how JPH2 mutant may trigger 
sudden cardiac death due to abnormal calcium handling, is focused on rearrangement of 
the ‘dyadic cleft’ which facillates cross talk of calcium channels.  The topic of HCM 
related sudden cardiac death as a consequence of dyadic cleft remodeling from JPH2 
mutation will be explored in Chapter II.  Considering the quiescent nature of various 
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HCM-causing mutant phenotypes, analysis of pathophysiology of different mutations can 
play a large role in modifying treatment management for an infamously asymptomatic 
disease.   
Treatment 
 Treatment for HCM is limited to addressing the symptoms which can arise due to 
ventricular obstructions and or arrythimia.  Antiarrythmics can be prescribed to stabilize 
heart rate and reduce the risk that is posed by the higher incidence of atrial fibrillation.  
Such drugs include the use of Beta-blockers or calcium channel blockers.  Since atrial 
fibrillation offers a higher risk of the development of thromboembolisms due to impaired 
blood flow, it is pertinent to prescribe anticoagulants such as heparin or warfarin to 
manage risk.  
 Due to the enlarged myocardium, the method of treatment should address 
symptoms that arise from impaired flow/pressure gradient within the ventricles.  
Symptoms such as chest pain or ischemia can be alleviated by prescribing beta blockers 
to reduce physical exertion of the heart.  Other treatments such as diuretics to maintain 
blood volume can be prescribed to also reduce the stress of contraction, although issues 
have to be addressed about hypotension and inherent risk of syncope in individuals with 
HCM.   
 More drastically, many invasive surgical procedures are used to treat severe cases 
of HCM from those with dysfunction in the physiology of the heart. Often times, 
procedures involve removing portions of the septum (septal myectomy) to relieve the 
ventricle of obstructions.  Patients showing a left ventricle pressure gradient of over 
50mmHg are often good candidates for this procedure as there is a relatively low risk 
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(<1%) operative risk with a high survival rates post procedure.  Often times a section of 
3-10 g of septal tissue is removed and is sufficient in alleviating symptoms caused by 
severe HCM.  Another form of myectomy can be performed by using high percentage 
alcohol injected into a coronary artery around the proximity of the obstruction to induce 




Chapter II: Sudden Cardiac Death in HCM as a Consequence of Architectural 
Changes in Dyadic Cleft due to JPH-2 Mutation 
 The majority of clinical manifestations of HCM are often consequence of physical 
obstructions due to hypertrophy of myocardial tissue in septum, left ventricle or the apex 
of the heart.  Enlargement of tissue cause patients to experience chest pain, increased 
oxygen demand in cardiac tissue, and abnormal valvular movements.  However, a 
hallmark clinical manifestation of HCM is within the increased incidence of Sudden 
Cardiac Death (SCD) in patients; a 3 - 6% mortality rate caused by sudden cardiac death 
is observed within the HCM patient population.  Although this is a relatively low 
mortality rate, diagnosis of SCD due to pre-existing HCM is often made postpartum.  In 
the study of HCM, the disease is often attributed to mutations in proteins coding for 
microfilaments of cardiac muscle tissue.  Mutations in genes encoding for myosin 
binding protein (MYH7 and MYBPC3) are observed in approximately 40% of the patient 
demographic.  However such mutations do not sufficiently explain the etiology of HCM-
onset SCD.  Studies suggest mutations in calcium channel are more directly related to the 
increased risk of sudden death in HCM patients (Blayney, 2009).  More specifically, 
mutations in the junctophilin-2 complex can manifest arrhythmic cardiac events leading 
to sudden death in those with HCM.  Decreased expression of functional Junctophilin-2 
remodels the normal geometry of the dyadic cleft. 
 Calcium ions play a paramount role in the contraction mechanism of muscle 
tissue, from binding to troponin C to allow for actin/myosin binding as well as cell 
depolarization events of muscle tissue.  In cardiac tissue, calcium influx events occur 
with synchrony via L-type calcium channels (LTCC). Disruptions in the calcium influx 
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can cause complications, which ultimately manifest as arrhythmic events.  Studies link 
the onset of arrhythmia in the ventricle to increased sensitivity to calcium ions.  The 
increased sensitivity may lead to shorter refraction periods before the initiation of another 
action potential to contract the myofilaments.  Abnormalities in calcium channel proteins 
may also induce problems associated with an increased risk of abnormal depolarization 
events.  The ability for proteolytic enzymes to degrade faulty channels is decreased as 
calcium influx is altered; this provides a positive feedback in which symptoms relating to 
the electrophysiological effects of such abnormalities continue to worsen (O’Mahoney, 
2012).   
Role of Coupled Receptors and Calcium Handling in Sacromere 
Since calcium influx is known to affect the synchrony of contractile rhythm of the 
heart, mutations affecting calcium channel proteins can give rise to dyssynchrony events 
leading to serious complications such as abnormal ventricular rhythms.  A mediator of 
proper calcium influx, the junctophilin membrane complex, helps couple the Ca
2+
 influx 
of LTCC and ryanodine receptors (RyR) (Landstrom, 2012).  This coupling of the two 
receptors maintains the geometry of the dyadic cleft; when coupled (LTCC and RyR) the 
influx of calcium helps develop action potentials for proper cardiac contraction.  LTCC is 
found in the T-tubules of the sacrolemma; T-tubules are the invagination of the muscle 
membrane (sacrolemma), which helps propagate the influx of calcium through the 
interior of the cell.  An extensive network of T-tubules is strewn throughout the 
sacrolemma to ensure that the membrane depolarization initiates a uniform action 
potential.  When the membrane of the sacrolemma is depolarized, LTCC releases a small 
amount of calcium ions which cascades the RyR receptors on the sacroplasmic reticulum 
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to release a large amount of calcium in its lumen, into the junction (dyadic cleft) initiating 
contraction of cardiac tissue (Blayney, 2009).  Figure 1 diagrams the subcellular 
organization and function of the couplon made by LTCC and RyR.  For proper 
propagation of contraction, the couplon of the RyR and LTCC must exist in a proper ratio 
(varies per species) as well as provide synchrony in the release of calcium into the cystol 
of the sacromere during systole (Heinzel, 2011).  Failure of synchrony leads to decreased 
force of contraction as well as reduction in filament overlap in the areas where 
contraction is delayed.   
 
Figure 4.  Organization of LTCC and RyR proteins. Couplons of proper dyadic 
geometry allows for function of Dyadic Space in Ca
2+
 Handling.  L-type calcium 
channels are strewn across the sacrolemma, in particular within the T-tubules, paired with 
RyR proteins on the sacroplasmic reticulum.  The overall positioning allows LTCC to 
initiate a Ca
2+
 spark to signal to RyR to release a larger influx of Ca
2+
 ions into the 
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cytosol; the area in between which mediates the crosstalk between the two channels 
called the dyadic cleft is shaded in grey.  Boxes in red and blue indicate conditions which 
would decrease or increase, respectively, the efficiency of local Ca
2+ 
release from the 
sacroplasmic reticulum.  
Although there are a large number of mechanisms which can affect Ca
2+
 
synchrony, change in the architecture of the dyadic space will be the focus of the 
investigation, in particular as a result of mutations in the expression JPH-2.  In the 
observation of the histology of cardiac myocytes, remodeling of the dyadic cleft is often 
present in hypertrophied myocytes.  The dyadic cleft spans the radius of 0.05µm between 
the T-Tubule and the sacroplasmic reticulum where the coupled calcium channels are 
located (Fan, 2009).   
The geometry of this space is important in localizing LTCC’s controlled 
triggering of RyR’s intracellular calcium release.  The density of the LTCC’s along the 
T-tubule in the couplon is important in carrying out calcium signaling along the dyadic 
cleft; hence the dyad geometry must accommodate for proper alignment of the LTCC and 
RyR channels to initiate effective signaling cascade (Fan, 2009).  On the molecular basis 
of an individual myocyte, as shown in Figure 2, the significance of the dyadic cleft is 
evident in localizing the initiation of Ca2
+
 ‘spark’; conversely, the mechanism of how 
LTCC and RyR couple to cascade throughout the entire contraction of heart is not 




Figure 5.  Mechanism of Interaction between LTCC and RyR mediated by the 
Dyadic Cleft.  The geometry of the dyadic cleft has its importance in localizing the Ca
2+
 
trigger from LTCC, allowing RyR to release the ionic contents within the lumen of the 
sacroplasmic reticulum.  The diagrammed subcellular event occurs throughout the heart 
to initiate contraction, although its exact mechanism of how this event propagates is 
unknown.  (Blayney, 2009) 
 The importance of maintaining the geometry in the dyadic space can be seen in 
the pathological effects of remodeling of the receptor coupling as a result of Hypertrophic 
Cardiomyopathy.  Relevant to abnormalities in the dyadic cleft due to HCM, are 
mutations downregulating the expression of junctophilin membrane complex proteins.  
Junctophilins (also called junctional complexes) help mediate the localization of Ca
2+
 
signaling between the sacrolemma and the sacroplasmic reticulum.  Junctophilins 
typically are membrane spanning proteins with a hydrophobic C-terminus as well as 
several functional domains which have affinity to the sacrolemma (OMIM: 605267).  A 
series of domains in junctophilins called the multiple membrane occupation and 
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recognition nexus (MORN) are believed to reconcile the calcium ‘crosstalk’ between the 
two membrane calcium channels (Landstrom, 2007).  Mutations in genes that express 
junctophilins often lead to pathogenesis involving dyssynchrony events linked to 
hyperplasia of cardiac tissue.   
Junctophilin-2 Mutations Linked to Rearranged Dyadic Cleft 
One type of junctophilin, Junctophilin 2 (JPH-2), is responsible for approximating 
calcium signaling of the T-tubule and sacroplasmic reticulum.  The level of expression of 
JPH-2 has a pivotal role in the onset of its own type of hypertrophic cardiomyopathy 
(hypertrophic cardiomyopathy type 17); this type is characterized by altered localization 
of the sacroplasmic reticulum as well as decreased Ca
2+ 
released from the lumen of the 
SR.  These observations can be related to the lack of physical approximation between the 
LTCC and RyR calcium channels; the change in density of LTCC causes an impaired 
Ca
2+
 spark to trigger release of a delayed or insufficient respons by the RyR to release 
lumenal Ca
2+
 in the SR.   
 Three different missense mutations in the exons coding for JPH-2 have been 
catalogued to introduce the onset of HCM (type 17):  S101R, Y141H, S165F.  S101R and 
Y141H mutation involves the MORN domain IV, and substitutes a hydrophilic amino 
acid for a basic (slightly hydrophobic) amino acid (Figure 3).  S101R mutation in 
particular, replaces a serine for an arginine amino acid in a protein domain responsible 
for sacrolemma affinity.  A similar mechanism, instead substituting a hydrophilic amino 
acid for a hydrophobic amino acid is also characteristic of the S165 mutation, however 
S165 indirectly inhibits a PKC phosphorylation site by removing the necessary hydroxyl 




Figure 6.  HCM associated mutations and functional domains on primary structure 
of JPH-2.  3 mutations, S101R, Y141H, and S165, occur within the MORN (membrane 
occupation and recognition nexus) Motif 1 region (on locations 1-126) is hypothesized to 
give proper localization between the dyadic cleft, in particular the T-tubules, since JPH-2 
spans the sacrolemma.  (Landstrom, 2007) 
 Experiments have linked the decreased expression of JPH-2 to decrease in Ca
2+
 in 
the intracellular junctions.  Mutations in junctional membrane complexes can cause 
LTCC to not be in the proper position to trigger a response to the RyR receptors.  This is 
evidenced in studies examining transient calcium levels in post-myocardial infarction 
mice (Landstrom, 2007)  The observed current through LTCC was normal, opposed to 
the intracellular calcium concentrations which were present in decreased levels.  In the 
event of under expressed JPH-2, a deficiency in the local positioning of the LTCC 
relative to the RyR leads in failure of Ryanodine receptors to release luminal SR Ca
2+
 
stores into the cytoplasm.  Failure of the dyadic space to mediate the couplon’s 
interaction, can lead to larger physiological conditionals quintessential to the symptoms 
of HCM.  Delayed action potential responses throughout the cardiac tissue cause 
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dysynchronous contraction in systole; dsynchronny within ventricular myocytes can lead 
to ventricular arrhythmia, hallmark of sudden cardiac death (Heinzel, 2011).  In addition, 
delayed action potentials reduce the overall force of contraction as a direct result of 
decreased summation in total synchronous sacromeric contraction.  Inefficient 
contraction involving overlaps in thin and thick filaments due to failures in the calcium 
pump can present the hallmark pathophysiology in hypertrophic cardiomyopathy.  Series 
of dyssynchronous contraction events exacerbate myocardial stress and the formation of 
myocardial scar tissue (myocardial fibrosis), affecting the parallel alignment of 
myocardial tissue, as seen in Figure 4.  The outcome of myocardial disarray can be seen 
as an indirect influence of propagation of uncoupled excitation due to a remodeled dyadic 
geometry.    
 
Figure 7.  Gross appearance and histology of myocardial disarray in HCM.  The 
image on the left shows hallmark signs of hypertrophied cardiac tissue, in particular the 
septum which is enlarged and gives a characteristic bent shape of the ventricular lumen.  
19 
 
Upon histological examination, myocytes are not aligned in normal parallel fashion, 
possibly due to asynchronous contractile events causing deformation of tissue.  (Kumar et 
al, 2013) 
Conclusion  
Junctophilin-2 plays in an important role in coupling proteins in the dyadic space 
to ensure the initiation of coupled excitation between LTCC and RyR receptors.  The 
effects of mutated JPH-2 are sufficient in incurring the pathogenesis seen in hypertrophic 
cardiomyopathy.  A type of HCM has been classified to describe HCM onset by a 
junctophilin-2 mutation, HCM-type 17.  Due to junctophilin-2’s interaction in facilitating 
proper localization of Ca
2+
, the pathogenesis of sudden cardiac death in type 17 HCM is 
related to the occurrence of improper calcium handling by the dyadic space (OMIM: 
613873).  The incidence of ventricular arrhythmia due to calcium asynchrony gives 
insight in screening for risk of sudden cardiac death based on genetic screening for JPH-
2.  By understanding the mechanism of how junctophilin mutations affect the overall 
pathology of HCM compared to myofilament mutations, a different approach in risk 










Chief Complaint:  
Patient’s reason for visit is due to increasing chest pain and shortness of breath 
after soccer practice. 
 
History of Present Illness:  
Paco, a 6 year old Hispanic male, presented with complaints of chest pain and 
shortness of breath.  The patient’s symptoms are often exacerbated by physical activities; 
Paco recalls several times after soccer practice where he feels uncomfortable in the chest, 
as if “squeezed” around torso.  Patient reports duration of pain from ‘a couple seconds’ to 
5 minutes; given on a pain scale of 1-10, the patient reports a 5-6 during episodes of chest 
pain..  Paco, who is always under his mother’s supervision during these games, has no 
reports of fainting after activity, although he did complain of slight dizziness and fatigue 
after a game 3 weeks prior to visit. Symptoms are reported by patient to have gotten 
progressively worse since his first episode.  In addition, Paco has recently been observed 
to develop a slight cough during his sleep.  The mother states Paco has experienced such 
symptoms for a period of 4 months, around the same time he joined Little League Soccer.  
He is currently not taking any medications to alleviate the symptoms. 
 
Past Medical History:   
Before the onset of symptoms, Paco has been a relatively healthy individual.  
Although Paco was born 2 weeks early, he has shown normal development throughout 
childhood.  His only admittance to the hospital was for a falling injury which required the 
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wound be stitched.  Besides his symptoms of chest pain and shortness of breath, Paco 
seems to be a relatively healthy child.  Since both of Paco’s parents work tight schedules 
around the night, Paco’s diet often consists of a high sodium fast food such as 
‘McDonald’s’ and etc.  Paco seems slightly overweight for his age, hence why his parents 
enrolled him in sports a couple months ago.  Paco is not currently on any medication nor 
does he have any known drug allergies. He also had a history of slight animal allergy 
when the family owned a dog.  Paco has no known other environmental allergies.  The 
patient is not exposed to tobacco smoke.  He has been living in the same house since his 
birth, which was built 2 years prior. His immunizations are also up to date. 
 
Family History: 
The patient is an only child of a couple in their early 30’s.  The father and his 
extended family have had a history of higher than normal cholesterol levels as well as 
hypertension.  The paternal grandfather, who is still living, has been previously 
diagnosed with dysmetabolic syndrome.  The father’s brother died at the age of 49 due to 
heart failure from poorly managed case of coronary heart disease.  
The mother is seen to be in relatively good health, with no known medical 
conditions.  The mother was sent to foster care where she was consequently adopted at a 
very young age (her sources say at ~2yo); the mother does not have any information of 







Paco is a 1
st
 grade student at a private school his parents have enrolled him in. He 
shows no learning disability and is excelling in his subjects; much of his time is spent 
reading books and playing soccer.  Socially, Paco shows no difficulty in communicating 
openly with his peers.  He is well-liked by much of his peers in class and his soccer team 
and shows no sign of social anxiety problems.  Although Paco lives with both his parents, 
he spends many nights under the supervision of a babysitter.  No abnormal behavior has 
been reported by the babysitter although she did report to the mother of slight episodes of 
coughing during his sleep. Paco does not live in a household with a history of smoking or 
drug abuse.  There are no signs of abuse from the parents.  Questions regarding the sexual 
history of Paco were not asked.   
 
Review of Systems: 
General: Denies weight loss, fevers, bed wetting.  Positive for coughing while sleeping 
[obstructive sleep apnea].  Fatigue and chronic chest pain as stated in HPI. 
HEENT: Last eye exam within 1 year, no auditory problems, no oral lesions. Last dental 
visit within 1 year.  Denies change in voice. 
Pulmonary: Cough present during sleep S.O.B upon exertion as stated in HPI.  
Cardiac: Chest pain and dyspnea upon exertion.See HPI 
Gastro.: No nausea, vomiting, difficulty swallowing.  Denies diarrhea, irregular passing 
of stools, and abnormal stool color. 




Heme.: Denies bruising or hemorrhagic problems 
Endo.: No thyroid problems, or hot/cold intolerance 
Vasc.:  No known information 
Neuro.: See HPI [Dizziness] 
Derm.: Denies rash and skin lesions  
Psych.: No history of depression or mood swings.   
 
Physical Examination: 
Vitals:  Weight: 59lbs  Height: 4’1”  BMI: 17.3 
  BP:  104/71  HR:  95  O2: 98% 
General:  Child with no signs of physical distress.  
Head:  NC/AT 
Eyes:  PERRLA 
Ears:  Normal external ears, canal and tympanic membrane.   
Nose: Symmetric with no signs of obstruction or inflammation.  
Mouth: Normal Dentition and pharynx.  No oral lesions or vesicles 
Neck: Thyroid is normal, Lymph nodes are normal, neck is supple. JVD 1cm above 
sternal angle; a-wave is slightly more prominent.   
Lymphatic: Adenopathy not present in cervical, supraclavicular, axillary, and inguinal 
areas.  
Lungs: Lung acoustics clear bilaterally. Percussion is resonant.  
Heart: Systolic ejection murmur 2/6 at lower left sternal border, increase in intensity after 
Valsava maneuver. S3 sound present  
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Abdomen: Normal bowel sounds, soft and non-tender.  
Rectal/GU:-no need to check- 
Back: No spinal deformities or tenderness of back 
Extremities:  Touch and sensation are intact.   
Skin: No rash or lesions present 
Musculoskeletal: Muscle tone and bulk is normal.  Strength is intact.  No sign of 
tenderness.   





 Figure 8. ECG of Paco Sanchez- ‘Dagger-like’ Q waves in lateral/ inferior leads I, II, 
IV, V3 and V6.  Prominent R wave in V1.  Findings show septal hypertrophy.  Image 









Figure 9. Parasternal Long axis view of 2-D echo of patient’s heart.  Septal (IVS) 
shows significant hypertrophy.  Posterior left ventricle wall also shows slight 
hypertrophy.  Wall thickness shown to be ~12mm in left ventricle. 
 
Laboratory Panels:  
Table 1. Lab Results for Paco Sanchez 
CBC 
 
Reference Range Units Values 
 




Hemoglobin 12.5 - 15.0  g/dL 13.1 
 
Hematocrit 31.0 - 43.0  % 37 
 
MCH 27.0 - 32.0 pg 30.5 
 
MCHC 32.0 - 36.7 g/dL 35.4 
 
MCV 77 - 103 cu  µm 86.04 
 












Neutrophil, segmented 32-62 % 49.5 
 




Lymphocyte 28-48 % 39.4 
 
Monocyte 3-6 % 4.6 
 
Eosinophil 0-3 % 2.7 
 
Basophil 0-1 % 0.2 
 





















70-105 mg/dL 86 
Renal 
Function 
    
 
BUN 5-20 mg/dL 16.3 
 
Creatinine, serum 0.5-0.8 mg/dL 0.6 
Electrolytes 
    
 
Chloride, Serum 96 - 108  mEq/L 99 
 
Calcium, Serum 8.8 - 10.8  mg/dL 9.5 
 
Sodium, serum 133 - 145 mEq/L 139 
 
Potassium, serum 3.3 - 5.1  mEq/L 5.1 
 
CO2 20-28 mEq/L 23 
Liver Function Test 
   
 
Albumin 3.8 - 5.4  g/dL 4.2 
 
ALT 4 - 40  U/L 8 
 
ALP 20-150 U/L 32 
 
AST 8-20 U/L 15 
 
Bilirubin 0.3-1.0 mg/dL 0.64 
Lipid Panel, fasting 
   
 
Cholesterol <200 mg/dL 160 
 
LDL 50-190 mg/dL 91 
 
HDL 30-70 mg/dL 56 
Pro-BNP 
 




0.074-0.457 U/L 0.263 
 
Reference Values from:  
1
 Gomella, L G, Haist, S A. Clinician’s Pocket Reference, 11th edition. Garden Grove, 
California: McGraw-Hill; 2007. 
2






Transvascular Endomyocardial Biopsy: 
 
Figure 10. Histology of patient’s myocardium.  Biopsy of tissue showing myocardial 
disarray in the septum of the patient.  Interstitial fibrosis may also be seen in the image. 
Genetic Screening 
Genetic screening for mutations in the sacromere tested positive for mutations in 
the MYBPC3 gene and JPH-2.  A missense mutation, S101R, was detected in JPH2 
coding region. 
 
Assessment and Differential 
Paco’s illness was presented with a pre-syncopic episode, dyspnea and stable angina 
upon exertion; these symptoms have been progressing for a period of 4 months in 
conjunction with Paco’s participation in sports.  A history of metabolic disorders is 
present in the paternal side, including the death of Paco’s uncle through cardiovascular 
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complications involving coronary artery disease; the maternal family history is unknown 
although the mother.  Upon physical exam, Paco exhibited a systolic murmur at the lower 
left sternal border, graded at 2/6; murmur sounds were intensified during when the 
Valsava Maneuver was applied.  Labs showed slightly elevated B-type natriuretic 
peptide; electrocardiography featured prominent ‘dagger-like’ Q-waves in lateral and 
inferior leads.  2-D echocardiography revealed hypertrophy of septal tissue and left 
ventricular wall at ~12mm.  Transvascular endomyocardial biopsy showed disarray of the 
myocardial cells in the septum as well as fibrosis of the cardiac interstitium. 
Based on the presentation of symptoms, shortness of breath, chest pain, 
propensity to syncope, the imaging of hypertrophied septal/ventricular cardiac tissue, and 
electrocardiographic abnormalities, the differential diagnoses may include: Hypertrophic 
Obstructive Cardiomyopathy, Athlete’s heart, Apical Hypertrophic Cardiomyopathy, 
Aortic Stenosis, Fabry’s Disease. Based on 2-D echocardiogram imaging and 
electrocardiogram readings strongly suggest Hypertrophic Obstructive Cardiomyopathy 
as the source of the patient’s symptoms.  Presentation of wall thickness at ~12mm puts 
the patient within the ‘grey zone’ diagnostic area between Hypertrophic Cardiomyopathy 
and Athlete’s heart, [normally at 13-15mm, age must be taken into account].  In addition 
to echo, and EKG imaging, biopsy of myocardial tissue also showed disarray in the cells 
of the septum; although it is often found in patients with HCM, it is not pathognomic of 
the disease.  The presence of pathological Q-waves (dagger-like) signifies the 
depolarization of an asymmetric septum; EKG readings in athlete’s heart are often 
characterized by non-pathological readings like sinus bradycaradia and an enlarged QRS 
voltage.  The location of the hypertrophied tissue at the septum and the posterior left 
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ventricular wall ruled out a non-obstructive, apical variant of myocardial hypertrophy.  
The lack of inverted T-waves in the precordial leads, sufficient ruled out Apical 
Hypertrophic Cardiomyopathy.  Aortic stenosis from congenital deformations of the 
aortic valve was also ruled out; murmur sounds after Valsava maneuver, normally 
decreased/unchanged in valvular obstructions, intensified correlating with hypertrophied 
tissue.  Fabry’s disease was out due to its X-linked recessive inheritance; since the 
mother is asymptomatic of Fabry’s disease, it is unlikely the patient is afflicted with this 
genetic disorder.  Fabry disease also results in lack of alpha galactosidase enzymatic 
activity as well as presence of renal failure; both of these facets were negative in the 
blood test.  
 
Treatment 
Due to the uncurable nature of Hypertrophic Cardiomyopathy and the increased 
risk of sudden cardiac death, Paco’s treatment requires a multi-faceted approach.  The 
patient’s young age requires risk management into the future to prevent the progression 
of the disease.  Paco is strongly advised to withdraw from sport programs to attenuate the 
exacerbation of symptoms.  Antiarrythmics and beta blockers are employed to treat 
symptoms of dyspnea and assists with ventricular relaxation.  Referral to a cardiologist is 
necessary to monitor Paco’s progress and determine further course of action. The 
patient’s mother and father are prompted to be evaluated by a geneticist for key 






1.  Verapamil 
80 mg PO q6- 8Hrs 
2.  Metoprolol tartrate 
25 mg PO bid 
3.  Disopyramide 
260 mg PO per day; 100mg prepared syrup bid 
Cardiologist Considerations: 
1.  Progression of symptoms should consider the implantable cardioverter device 
2.  Modification to prescription regimen if needed 
Genetic Screenings: 
1.  Genotypic screening for mutation in: MYH7, MYBPC3, JPH-2, TNNT2 
2.  First degree relative screening: 
 Screening of father due to cardiac complications in the family 
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